Mutations in the Nucleotide Binding Domain 1 Signature Motif Region Rescue Processing and Functional Defects of Cystic Fibrosis Transmembrane Conductance Regulator ΔF508*

  1. John L. Teem
  1. From the Department of Biological Science, Florida State University, Tallahassee, Florida 32306

Abstract

The gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR), an ATP binding cassette (ABC) transporter that functions as a phosphorylation- and nucleotide-regulated chloride channel, is mutated in cystic fibrosis (CF) patients. Deletion of a phenylalanine at amino acid position 508 (ΔF508) in the first nucleotide binding domain (NBD1) is the most prevalent CF-causing mutation and results in defective protein processing and reduced CFTR function, leading to chloride impermeability in CF epithelia and heterologous systems. Using a STE6/CFTRΔF508 chimera system in yeast, we isolated two novel ΔF508 revertant mutations, I539T and G550E, proximal to and within the conserved ABC signature motif of NBD1, respectively. Western blot and functional analysis in mammalian cells indicate that mutations I539T and G550E each partially rescue the CFTRΔF508 defect. Furthermore, a combination of both revertant mutations resulted in a 38-fold increase in CFTRΔF508-mediated chloride current, representing 29% of wild type channel activity. The G550E mutation increased the sensitivity of CFTRΔF508 and wild type CFTR to activation by cAMP agonists and blocked the enhancement of CFTRΔF508 channel activity by 2 mm 3-isobutyl-1-methylxanthine. The data show that the ΔF508 defect can be significantly rescued by second-site mutations in the nucleotide binding domain 1 region, that includes the LSGGQ consensus motif.

  • Abbreviations:
    CF
    cystic fibrosis
    CFTR
    CF transmembrane conductance regulator
    ABC
    ATP binding cassette
    NBD
    nucleotide binding domain
    PKA
    CAMP-dependent protein kinase
    wt
    wild type
    FRT
    Fischer rat thyroid
    IBMX
    3-isobutyl-1-methylxanthine
    ANOVA
    analysis of variance
    MRP
    multidrug resistance-related protein
    • Received June 7, 2002.
    • Revision received July 9, 2002.
    Table of Contents

    Submit your work to JBC.

    You'll be in good company.